Introduction
Prion diseases are spongiform encephalopathies related to the cellular prion protein (PrP c ) abundantly expressed in the central nervous system (CNS) (Prusiner, 1998) . Infectious forms are attributed to entrance into normal brain of a proteinaceous particle that leads to accumulation of an abnormally folded form of the protein (scrapie form, or PrP sc ) as a consequence of conformational conversion of the endogenous PrP c (for reviews, see Prusiner, 1998; Will et al., 1999) . Genetic forms were traced to several mutations in PrP c (for reviews, see Gambetti et al., 1999; Weissmann et al., 1999) . In contrast, most cases of prion disease, known as sporadic forms, can neither be attributed to a previous infection nor present identi®ed germline mutations (for reviews, see Prusiner, 1998; Will et al., 1999) , and are supposed to occur by stochastic conversion of PrP c into the abnormal form.
These transmissible encephalopathies are viewed as gain-of-function diseases due to accumulation of PrP sc because little evidence is available that the loss of PrP c following conformational conversion has a role in pathogenesis. Notwithstanding this, the possibility that prion diseases have loss-of-function components remains open (Aguzzi and Weissmann, 1997; Samaia and Brentani, 1998) , and a critical examination of this hypothesis depends on determining the elusive functions of PrP c in the CNS.
Attempts to unravel these functions by gene knockouts produced controversial results. An early study reported no developmental nor behavioral abnormalities in mice with deletion of the Prnp gene open reading frame (ORF) (Bueler et al., 1992) . However, aberrant sleep patterns were found in Prnp knockout mice (Tobler et al., 1996) . In addition, while inhibitory avoidance learning and anxiety were similar in wild-type and PrP 0/0 mice, the latter showed increased locomotor activity . Electrophysiological abnormalities were also described in the brains of PrP 0/0 mice (Collinge et al., 1994; Colling et al., 1996) , but were not con®rmed in other laboratories (Herms et al., 1995; Lledo et al., 1996) . Nonetheless, mice lacking PrP c were more sensitive than wild-type animals to seizures induced by various convulsant agents .
In contrast to the early Prnp knockouts (Bueler et al., 1992) , aging mice in which the ORF was deleted together with large portions of both a 5¢ intron and the 3¢-untranslated region suffered extensive cerebellar degeneration with progressive ataxia (Sakaguchi et al., 1996) . The pattern of expression of the PrP c gene homolog Doppel may explain the controversial results of various Prnp knockouts. The explanation is based on possible toxicity of the Doppel protein, which is overexpressed selectively through abnormal splicing following intronic deletions, but not following ORF deletions of the Prnp gene, while toxicity is abolished by the presence of a single wild-type Prnp allele (Moore et al., 1999; Wong et al., 2001) .
In addition, copper binding (Brown et al., 1997a) endows PrP c with antioxidant activity, and it has been proposed that loss of PrP c may cause neurodegeneration through increased oxidative stress (for a review, see Wong et al., 2000) . Antioxidant properties of PrP c may also be linked to abnormal synaptic activity (for reviews, see Wong et al., 2000; Brown, 2001) , which may in turn explain electrophysiological abnormalities detected in some studies of Prnp knockouts.
On the other hand, the introduction into PrP 0/0 of N-terminally truncated Prnp alleles lacking either residues 32±121 or 32±134 led to extensive cerebellar degeneration and astrocytosis accompanied by marked ataxia, which were absent with shorter truncations up to residue 106, and were abrogated by the presence of a wild-type Prnp allele (Shmerling et al., 1998) . The authors proposed that truncated PrP c molecules compete with other PrP-like molecules for a common ligand. Their results, however, also suggest that deleted domains of PrP c that lead to neurological defects may be essential for the normal functions of PrP c . All deletions examined by Shmerling et al. (1998) , and not only those that result in neurodegeneration, removed the N-terminal copper-binding octarepeats (Brown et al., 1997a; Aronoff-Spencer et al., 2000; Whittal et al., 2000) , suggesting that other factors besides copper, and related to residues 106±134 of the cellular prion protein, are associated with resistance to neurodegeneration.
Several molecules are capable of interacting with PrP c (Kurschner and Morgan, 1995; Yehiely et al., 1997; Rieger et al., 1997; Graner et al., 2000) . In a previous study, a predicted PrP c -binding peptide was designed on the basis of the complementary hydropathy theory (see, for example, Bost et al., 1985; Brentani, 1988; Boquet et al, 1995) , and an antibody raised against this peptide recognized a 66 kDa cell surface molecule that binds PrP c (Martins et al., 1997) . The immunogenic peptide used in the previous study corresponds to the DNA strand complementary to that of the human Prnp gene that codes for amino acids 114±129 (Martins et al., 1997) . The speci®ed amino acid sequence is contained within the domain critical for degenerative effects of PrP c N-terminal deletions (Shmerling et al., 1998) . We therefore reasoned that the immunogenic peptide might be useful as a probe to test the hypothesis that PrP c is involved in mechanisms of cell death.
We examined whether the PrP c -binding peptide affects programmed cell death in an in vitro preparation of organotypical retinal explants. This preparation has been used as a model for studies of cell death in the CNS because it maintains the structure of the retinal tissue (for reviews, see Linden et al., 1999; Linden, 2000) . The experiments show that, upon engagement with the PrP cbinding peptide as well as with certain antibodies, PrP c transduces neuroprotective signals that affect the sensitivity to induced cell death.
Results
Cellular prion protein is expressed abundantly in the developing retina In newborn rats, the retina contains three strata ( Figure 1A) . The innermost ganglion cell layer (GCL) contains the ganglion cells that project to subcortical visual centers along the optic nerve. The outer cellular stratum is separated from the GCL by the inner plexiform layer (IPL), and contains a few rows of early developing amacrine cells (inner nuclear layer; INL), plus a proliferative zone called the neuroblastic layer (NBL). Besides proliferating cells, the NBL contains post-mitotic cells that recently have left the cell cycle and are migrating towards their de®nitive positions (for a review, see Linden et al., 1999) .
A monoclonal antibody to PrP c produced immunolabeling across the retina ( Figure 1B ). Cell somas were stained in the NBL, in a pattern consistent with the membraneassociated location of the endogenous PrP c . A few labeled pro®les close to the INL resembled migrating cells. Detergent permeabilization of the cryosections resulted in more diffuse labeling, consistent with either increased cytoplasmic labeling or partial release of the glycosylphosphatidylinositol (GPI)-anchored PrP c . Cell somas in both the INL and GCL were also labeled, slightly more intensely in peripheral than in central areas of the retina (data not shown). A similar labeling pattern was obtained with a non-commercial polyclonal antibody (N10, provided by Dr Stanley Prusiner, data not shown), while control sections processed without the primary antibody were unlabeled ( Figure 1C ). In addition, antibodies raised against the cellular prion protein speci®cally recognized PrP c in western blots of protein extracts from retinal tissue of wild-type, but not of PrP 0/0 mice ( Figure 1D ). Thus, PrP c is expressed abundantly in the neonatal rodent retina.
A PrP c -binding peptide prevents apoptosis in retinal tissue
We have shown previously that death of ganglion cells, whose axons are damaged when retinal explants are prepared, is blocked by the inhibitor of protein synthesis anisomycin (ANI). However, ANI induces cell death among recent post-mitotic cells within the NBL (Rehen et al., 1996 . To test for effects upon retinal cell death, we used a PrP c -binding peptide (Martins et al., 1997) , herein called PrR, and a scrambled peptide, containing the same 16 amino acids as PrR in a distinct order, with a hydropathic pro®le that is non-complementary to PrP c . The properties of these peptides in a binding assay conformed to their theoretically predicted behavior, and deletion of the putative binding site in PrP c abrogated binding of PrR ( Figure 4A and B)
Cell death was quantitated in rat retinal explants, by counting the pyknotic, homogeneously stained pro®les ( Figure 1E ) that correspond to dying cells (Rehen et al., 1996) . The PrR peptide had no effect on ganglion cell death, which was completely blocked by ANI ( Figure 2A ). In contrast, PrR reduced ANI-induced cell death by~50% in the NBL ( Figure 2C ). The effect was less than with forskolin, which completely abolished ANI-induced cell death in the NBL ( Figure 2C ). The scrambled peptide had no effect (Figure 2B and D) .
Degenerating pro®les in the NBL can be stained with both the TUNEL technique ( Figure 1F ) and with an antibody to the activated form of caspase-3 (Namura et al., 1998) , indicating that cell death is at least in part due to apoptosis. The PrR peptide also signi®cantly reduced the incidence of TUNEL-positive pro®les in the NBL ( Figure 2E ).
Concentrations of the PrR peptide between 2.5 and 25 mM yielded little effect upon cell death in the NBL, whereas either 80 or 200 mM signi®cantly reduced anisomycin-induced cell death to 58.7 6 2.8 and 61.2 6 5.8% of control values, respectively ( Figure 2F ; means 6 SEM, n = 15 and 9, respectively).
Neuroprotection by the PrP c -binding peptide depends on PrP c Hydrolysis of GPI anchors releases PrP c from the plasma membrane and is expected to block PrP c -mediated effects. Since the half-life of PrP c has been estimated at~6 h (Taraboulos et al., 1992) , and ANI at 1 mg/ml blocks (F) Dose±response curve for the PrR peptide, either in the presence (®lled circles) or in the absence of anisomycin 1 mg/ml. Each data point is the mean 6 SEM of 8±16 explants from a total of ®ve experiments, and normalized with respect to the rate of cell death (100%) induced by anisomycin. *P < 0.01 versus anisomycin alone.
protein synthesis almost completely in retinal tissue (Rehen et al., 1996) , replenishment of surface PrP c during a 24 h treatment with ANI following hydrolysis of GPI anchors is unlikely. Treatment of rat retinal explants with phosphatidylinositol-speci®c phospholipase C (PI-PLC) abolished the neuroprotective effect of the PrR peptide. In these conditions, the enzyme had no effect upon either ganglion cell death or ANI-induced cell death in the NBL, nor upon the protective effect of forskolin. The only observable effect was upon the protective action of PrR ( Figure 3A and B).
Likewise, ANI induced apoptosis in the NBL of both wild-type and PrP 0/0 mice, while preventing ganglion cell death. Similarly to rat retina, the PrR peptide reduced the rate of cell death by~50% in the NBL of wild-type mouse retinal explants ( Figure 3C ), but had no effect upon explants from PrP 0/0 mice ( Figure 3D ). In contrast, forskolin counteracted ANI-induced cell death in both wild-type and PrP 0/0 explants.
The preceding experiments suggested that protection by the PrR peptide depends on the presence of the endogenous PrP c on the surface of the retinal cells. It is, however, conceivable that interaction of PrP c with the 66 kDa PrP c -binding protein (Martins et al., 1997) may sensitize retinal cells to degeneration, and that the peptide might reduce cell death by competing against the 66 kDa protein for the binding site in PrP c .
To test this hypothesis, we used a human neurotoxic peptide (106±126), which is similar to the sequence of amino acids 105±125 in both rat and mouse PrP c , and induces cell death in dissociated brain cell cultures, depending on the presence of the endogenous PrP c and mediated by glia (Forloni et al., 1993; Giese et al., 1998; Brown, 1999 Explants from rat retinas were pre-treated (PRE) with either vehicle or PI-PLC, then washed and treated with various combinations of anisomycin (1 mg/ml), the PrR peptide (80 mM) and forskolin (10 mM). Note that PI-PLC treatment prevents the neuroprotection by the PrR peptide in the NBL. *P < 0.01 versus anisomycin alone. (C and D) Neuroprotection by the PrR peptide occurs in the retina of wild-type (C), but not Prnp-knockout mice (D). Data are means 6 SEM counts of pyknotic pro®les from triplicate explants. *P < 0.01 versus anisomycin alone. Incubation of retinal explants with the NTX peptide did not lead to cell death above control levels. This is probably due to the use of fresh solutions prepared immediately before the experiments, while it has been shown that only aged solutions of NTX may cause retinal cell degeneration (Ettaiche et al., 2000) . In addition, in contrast to the PrR peptide, NTX did not block ANI-induced cell death ( Figure 4C ). However, pre-incubation of NTX with PrR abolished the neuroprotective effect of the latter ( Figure 4D ). The results are consistent with the hypothesis that rather than disruption of PrP c ±p66 binding, it is the interaction of PrP c with PrR that induces neuroprotection.
PrP c -binding peptide activates both the cAMPdependent protein kinase and the Erk pathways in the retina Incubation of retinal explants from wild-type mice with the PrR peptide was followed by an increase in the intracellular concentration of cAMP, which was not observed in similarly treated PrP 0/0 explants ( Figure 5A ).
The activity of protein kinase A (PKA) was also increased in wild-type retinas incubated with the peptide, to a level close to that with the D1-dopaminergic agonist 6-Cl-PB. The latter result is consistent with the presence of functional D1-like receptors in the retina of developing rodents (e.g. Shearman et al., 1997) . In contrast, PKA activity was not increased above resting levels in PrP 0/0 explants treated with the peptide (Figure 5B) . However, the levels by which forskolin stimulated PKA relative to unstimulated controls were similar in both wild-type and PrP 0/0 explants (data not shown). Interestingly, both the basal, unstimulated levels of cAMP and the resting activity of PKA were higher in PrP 0/0 retina than in wild type.
The PrR peptide also activated the Erk pathway. Both the level of Erk phosphorylation (data not shown) and the ability of the activated enzyme to phosphorylate its substrate Elk-1 ( Figure 5C ) were increased in wild-type retinas treated with the PrR peptide. Densitometric measurements (means 6 SEM from three independent experiments) indicated a fold increase of 2.4 6 0.3 in phospho-Elk detection following incubation with immunoprecipitated phospho-Erk from wild-type mouse retinas treated with the PrR peptide, relative to untreated controls. In contrast, there was no difference between treated and untreated PrP 0/0 retinas, albeit that the basal activity of the Erk pathway was higher in PrP 0/0 than in wild-type retinas, similar to the results with cAMP/PKA (phospho-Elk detection, fold increase of 3.3 6 0.4 in material from untreated and 2.7 6 0.4 in material from PrR-treated retinas of PrP 0/0 mice, relative to untreated wild-type controls).
Neuroprotection by the PrP c -binding peptide is mediated by activation of cAMP-dependent protein kinase Rp-cAMPs, a competitive inhibitor of PKA, consistently blocked neuroprotection by PrR ( Figure 5D ). The stereoisomer Sp-cAMPs, an activator of PKA, blocked ANIinduced cell death by itself, consistent with the effect of forskolin ( Figure 5E ). In contrast, PD098059, an inhibitor Retinal explants from neonatal rats were treated with anisomycin (1 mg/ml), the PrR peptide (PrR 80 mM) in the presence of either 100 mM Rp-cAMP-s (D) or 100 mM Sp-cAMP-s (E), respectively an inhibitor and an activator of cAMP-dependent protein kinase, or in the presence of 30 mM PD98059, an inhibitor of the Erk-activating MEK enzyme (F). Note the reversion of the neuroprotective effect with the PKA inhibitor, and the potentiation of the neuroprotective effect with the Erk pathway inhibitor.
of the Erk-activating enzyme MEK, potentiated the protective effect of the PrR peptide ( Figure 5F ). PD098059 consistently showed a protective effect against ANI-induced cell death, indicating that Erk activation in the immature retina has a pro-apoptotic effect, as shown by other experiments from our laboratory (C.B.L.Campos, P.-A.Be Âdard and R.Linden, unpublished results).
Effects of antibodies to PrP c upon cell death correlate with their action upon cAMP
Two polyclonal antisera raised in rabbits against either recombinant mouse PrP c or the NTX peptide prevented protection by the PrR peptide ( Figure 6A ), presumably either by competing for the same binding site or by steric hindrance. These results are consistent with the interpretation that interaction of PrP c and the PrR peptide induces neuroprotection.
In contrast, a third antiserum raised against PrP c in PrP 0/0 mouse led to a 50% reduction of ANI-induced cell death in rat retina ( Figure 6B ). The neuroprotective antiserum had no effect upon the retinal tissue from PrP 0/0 mice ( Figure 6C ), supporting the hypothesis that the protective effect depends on PrP c . The rabbit antisera that antagonized neuroprotection by the PrR peptide had no effect upon the intracellular concentration of cAMP in either wild-type or PrP 0/0 tissue, whereas the neuroprotective mouse antiserum against PrP c induced an increase in the intracellular concentration of cAMP in wild-type, but not in PrP 0/0 retinal tissue ( Figure 6D ). Thus, an agonist neuroprotective effect of antibodies to PrP c correlates with their ability to induce an increase in intracellular cAMP.
Discussion
This investigation showed that: (i) a peptide that binds residues 113±128 of the mouse (114±129 human) cellular prion protein (the PrR peptide) induces a neuroprotective response in the neuroblastic layer of the developing retina in vitro; (ii) this neuroprotective response depends on the presence of endogenous PrP c at the surface of the retinal cells; (iii) the PrR peptide activates both the cAMP/PKA and the Erk signaling pathways in the retina; (iv) neuroprotection by the PrR peptide is mediated by the activation of a cAMP-dependent protein kinase pathway; and (v) antibodies to PrP c that induce an increase in the concentration of intracellular cAMP also induce a PrP c -dependent neuroprotective response.
Both cAMP-dependent protein kinase and Erk signaling pathways were activated by the PrR peptide in wild-type retinas, but not in PrP 0/0 retinas. We have shown previously that cAMP protects cells in the NBL, but not ganglion cells, from degeneration (Rehen et al., 1996; Varella et al., 1997 Varella et al., , 1999 Silveira et al., 2002) , which is consistent with neuroprotection restricted to the NBL in the current experiments. However, preliminary data show that the PrR peptide also protects from induced degeneration both photoreceptors subject to thapsigargin-induced cell death in older retinas and NIH-3T3 cells subject to cell death induced by blockade of protein synthesis (data not shown), indicating that a neuroprotective function of PrP c may be widespread. In contrast, activation of Erk was found associated with cell death in the NBL of retinal explants. Indeed, inhibition of PKA activity blocked the effect of the PrR peptide, whereas inhibition of the Erk pathway potentiated the PrP c -mediated neuroprotection. The balance between the pro-degenerative Erk and the neuroprotective PKA pathways may also explain why the PrR peptide led to a maximum effect of 50% on ANIinduced cell death, since concurrent inhibition of the Erk pathway potentiated neuroprotection by the PrR. The data suggest that PrP c may function as a trophic receptor, stimulation of which leads to a neuroprotective state through the engagement of a cAMP/PKA pathway. The neuroprotective effect of antibodies that increase the intracellular concentration of cAMP supports both the proposal that PrP c is a signaling molecule and the involvement of the cAMP/PKA pathway in the transduction of the PrP c -mediated signals.
It is, however, not clear how the GPI-anchored PrP c attached to the outer membrane lea¯et may lead to the activation of adenylyl cyclase, which normally is regulated by G-proteins associated with the inner membrane lea¯et. Various GPI-anchored surface proteins transduce signals for proliferation, secretion of cytokines, oxidative bursts and apoptosis in leukocytes and lymphoid cell lines (for a review, see Horejsi et al., 1998) . Signaling was shown to involve tyrosine phosphorylation, mobilization of intracellular Ca 2+ and, in a few instances, production of phosphoinositides and diacylglycerol, but no increases in cAMP have been reported following cross-linking of GPIanchored proteins (Horejsi et al., 1998) . Nevertheless, heterotrimeric G-proteins were shown associated with GPI-anchored proteins in low density detergent-insoluble membrane domains (Solomon et al., 1996 (Solomon et al., , 1998 Lisanti et al., 1999; Oh and Schnitzer, 2001) . It is likely that an association of PrP c with G-proteins within the membrane compartments that contain PrP c (Gorodinsky and Harris, 1995; Vey et al., 1996; Naslavsky et al., 1997) may explain the activation of adenylyl cyclase leading to downstream neuroprotection.
A recent study showed that antibody cross-linking of PrP c led to caveolin-1-dependent activation of the tyrosine kinase Fyn in a neuroectodermal cell line (MouilletRichard et al., 2000) , but only when subject to a differentiation program, and restricted to neurites. Although that study indicated that PrP c may function as a signal transduction protein, the authors failed to obtain a morphological response downstream of Fyn. It remains to be tested whether tyrosine kinases are also associated with the PrP c -mediated neuroprotection. Prevention of cell death induced by overexpressed Bax has been also reported after overexpression of PrP c in primary human neurons, but the effect seems to depend strictly on the N-terminal domains of the relatively rare transmembrane forms of PrP c (Bounhar et al., 2001) .
Immortalized cell lines derived from Prnp ±/± hippocampal cells were more sensitive to apoptosis induced by serum withdrawal than independent wild-type cell lines, whereas expression of either PrP c or Bcl-2 protected these cells from apoptosis (Kawahara et al., 1999) . These data are also consistent with a cell-protective function of PrP c . In addition, PrP 0/0 cerebellar cells are more sensitive than wild-type cells to oxidative stress (Brown et al., 1997b) . This enhanced sensitivity was attributed to decreased superoxide dismutase activity associated with copper metabolism (Brown et al., 1997b; Brown and Besinger, 1998; Wong et al., 2000) . Preliminary data from our laboratory show that the antioxidant ascorbic acid can prevent ANI-induced cell death in retinal explants (M.H.Varella, F.G.de Mello and R. Linden, unpublished results) . Links between the resistance to oxidative stress mediated by PrP c (Wong et al., 2000) and the protective effect of PKA activation remain to be established.
If indeed PrP c transduces neuroprotective signals, then why do PrP 0/0 mice show no obvious spontaneous neuronal death? One possibility is that the lack of PrP c from the earliest stages of embryogenesis may trigger compensatory responses in the intricate signaling network that feeds into the cell death execution mechanisms. For example, PrP 0/0 retinas had a higher level of both PKA and Erk basal activities than wild type, showing that a variety of changes in signaling pathways within the retina accompany PrP c deletion. In contrast, a recent study showed that acute deletion of PrP c in adult mice does not lead to spontaneous neurodegeneration (Malluci et al., 2002) , which might be taken as evidence against the relevance of PrP c -mediated neuroprotection, at least with respect to prion diseases. Notwithstanding this, it has not been reported whether neurons acutely depleted of PrP c may have become more sensitive to insults such as, for example, oxidative stress (Brown et al., 1997b) . In addition, short-term compensatory changes in signal transduction pathways, such as the cAMP/PKA and Erk signaling pathways, have not been examined in the conditional knockout experiments (Malluci et al., 2002) . Clearly, ruling out that the loss of PrP c function may be relevant for pathogenesis of prion diseases will require further experimentation.
The kinetics of cell loss in various models of neurodegenerative disease suggest that cell death in inherited neurodegenerations is a consequence of single catastrophic events imposed on an altered homeostatic state, instead of the traditional hypothesis of cumulative damage (Clarke et al., 2000) . The present data are consistent with the view that the sensitivity to degeneration within the retinal tissue is controlled by a network of biochemical pathways . The data show that PrP c feeds into this network as a neuroprotective receptor, and suggest that engagement of PrP c helps maintain retinal cells in a steady state removed from the cell death execution pathways (cf. Clarke et al., 2000) .
An antiserum to the PrR peptide also recognizes a PrP cbinding protein of 66 kDa on the surface of cells within the CNS (Martins et al., 1997) . Cross-immunoreactivity of both the PrR peptide and the p66 PrP c -binding protein raises the possibility that the latter may be the natural trophic agent that leads to activation of PrP c . We recently have identi®ed the p66 PrP c -binding protein as the stressinduced protein 1 (STI1), which contains a peptide domain with a hydropathy pro®le that corresponds to the PrR peptide used here as a probe (Zanata et al., 2002) . The evidence for neuroprotection triggered either by STI1 or by the relevant peptide (Zanata et al., 2002) further support the neuroprotective signaling function of PrP c described here. Understanding PrP c -mediated neuroprotection is a major requirement to evaluate possible loss-offunction components in the pathogenesis of prion diseases.
Materials and methods

Animals
Lister hooded rats from our inbred colony, PrP 0/0 mice from an inbred colony originally derived from mice of the Zurich knockout type kindly provided by Drs Charles Weissmann (Imperial College London) and Hans Kretzschmar (University of Munich), and wild-type control mice from an inbred C57BL6/J 3 129 mixed lineage with a genetic background similar to the knockout animals were used in these experiments.
Tissue culture Rodents at postnatal days 1 and 2 were killed by decapitation, and their eyes rapidly removed. The retinas were dissected and pieces of~1 mm 2 were cut in culture medium (BME, Gibco-BRL, with 5% fetal calf serum) and incubated at 37°C in 5% CO 2 and 95% air in an orbital shaker at 80±90 r.p.m. The tissue was ®xed by immersion in 2±4% paraformaldehyde in phosphate buffer pH 7.2 for at least 40 min, followed by 20% sucrose in the same buffer. The explants were oriented under a dissecting microscope in an aluminum chamber with OCT embedding medium, and 10 mm thick transverse sections were cut in a cryostat. Neonatal rat eyes were ®xed in situ, and frozen sections were prepared similarly.
Immunohistochemistry and western blot Sections were reacted with either monoclonal antibody 6H4 to amino acids 144±152 of human prion (Prionics) or polyclonal antibody N10 against prion (kindly provided by Dr S.B.Prusiner). Control sections were processed in parallel without the primary antibody. Permanent staining was obtained with an HRP-ABC kit (Vector) using diaminobenzidine as chromogen.
For western blots, retinas from either wild-type or PrP 0/0 mice were dissected as described and extracts were prepared by direct tissue lysis in Laemmli buffer. Samples were resolved by SDS±PAGE and transferred to a nitrocellulose membrane. Blots were exposed to either an anti-PrP c antibody raised in PrP 0/0 mouse (1:500; Lee et al., 2001) or monoclonal antibody 6H4 to amino acids 144±152 of human prion (Prionics) for 16 h at 4°C, washed three times with TBST (40 mM Tris pH 7.4, 120 mM NaCl and 0.05% Tween-20), followed by addition of peroxidase-labeled anti-mouse IgG. The reaction was developed using enhanced chemiluminescence (Amersham Pharmacia Co.). Loading controls were performed by western blot with an antibody to actin (Sigma, 1:200) .
Treatments
Drugs were added at the beginning of a 24 h incubation period. ANI was stocked in water at 500 mg/ml and applied at 1 mg/ml. Forskolin (Calbiochem) was stored at 10 mM in dimethylsulfoxide (DMSO) and applied at 10 mM. We had determined that DMSO at up to 1% had no effect upon cell death in the retinal explants (data not shown). Peptides HVATKAPHHGPCRSSA (PrP c -binding peptide; PrR), KSRGHVHC-HAPAPATS (scrambled; SCRA) and KTNMKHMAGAAAAGA-VVGGLG (neurotoxic; NTX) were synthesized chemically and their purity was tested by HPLC (Neosystems, Immunograde). Stocks were prepared at 20 mg/ml in BME with HEPES 20 mM pH 7.2, and 0.8% DMSO for NTX.
PI-PLC (Sigma) was diluted at 4 mg/ml in BME with 12% glycerol (v/v), 2 mM Tris±HCl pH 8.0 and 2 mM EDTA, and explants were preincubated for 1 h at 37°C. Then the tissue was washed three times in 15 ml of BME and incubated with the drugs as above.
Antibodies used in functional tests included: a rabbit antiserum raised against the chemically synthetized NTX, produced by Neosystems (Strasbourg, France), and its pre-immune control; rabbit antisera raised against either GST or GST±moPrP c ; and polyclonal antisera raised in PrP 0/0 mouse against His 6 -moPrP c as well as pre-immune controls, all produced at the Ludwig Institute, SP. All antisera used in this study speci®cally recognize PrP c in western blots of protein extracts from rodent brains (data not shown).
Detection of cell death
Cell death was detected either as condensed, pyknotic pro®les stained with neutral red, or with the TUNEL procedure, using either¯uorescent Apoptag (Intergen) or permanent FraGel kits (Oncogene). We have shown previously that counts of anillin-stained condensed, hyperchromic pro®les adequately represent cell death as con®rmed with other methods such as TUNEL staining for apoptosis (Rehen et al., 1996; Varella et al., 1997) . In each experiment, at least three microscopic ®elds delimited by an eyepiece graticule of 0.0148 mm 2 were counted in 3±8 explants per group. Statistical analysis was performed by analysis of variance followed by planned comparisons using Duncan's multiple range test, using SPSSPC software.
Binding and competition assays
PrR peptide conjugated to bovine serum albumin (BSA) was biotinylated with Sulfo-NHS-LC-biotin (Pierce). Increasing amounts (2.5±500 ng) of either the biotinylated conjugate or biotinylated BSA, as a non-speci®c binding control, were incubated for 90 min at room temperature with 0.25 mg of either heterologous expressed wild-type His 6 -moPrP c or His 6 -moPrP c with amino acids 105±128 deleted (His 6 -moPrP c D105±128), immobilized on an ELISA plate (Covalink). Following two washes with phosphate-buffered saline (PBS) and incubation with avidin±peroxidase (Sigma) 1:1000, 1 h at room temperature in the dark, the reaction was developed with o-phenylnedramine-2HCl (OPD) (Sigma). Absorbance was measured in a Benchmark microplate reader (Bio-Rad) at 490 nm.
For the competition assay, increasing amounts of either scrambled (6.25, 31.25 or 62.5 mg) or non-biotinylated PrP c -binding (6.25, 31.25, 62.5 or 75 mg) peptides were pre-incubated with 0.25 mg of His 6 -PrP c for 90 min at room temperature. Then, 0.125 mg of the biotinylated conjugate was added, and incubated for a further 90 min at room temperature. The neurotoxic peptide (0.31 or 1.25 mg) was pre-incubated with the biotinylated conjugate for 90 min before adding it to adsorbed His 6 -PrPc. After two washes with PBS pH 7.4, samples were developed as described above.
Second messenger and kinase assays Treatments. Retinas of P2-3 mice were pre-incubated with 100 mM IBMX for 1 h at 37°C, and then treated with 80 mM of either PrR or scrambled peptides for 10 min. Controls were kept in Dulbecco's modi®ed Eagle's medium (DMEM).
cAMP. The tissue was washed with PBS pH 7.4 and homogenized with ice-cold 5% trichloroacetic acid. The homogenates were centrifuged at 4°C at 4000 g for 15 min, and the supernatants were extracted three times with ether acidi®ed with 0.1 M HCl, and the aqueous phase dried in a speed-vac concentrator (Savant). The residues were dissolved in Tris-EDTA buffer pH 7.5. The concentration of cAMP per mg of protein was determined with a DPC kit (Diagnostic Products Corporation, Los Angeles, CA), according to the manufacturer's instructions.
cAMP-dependent protein kinase activity. The tissue was washed with PBS pH 7.4 and homogenized with ice-cold extraction buffer (5 mM EDTA, 50 mM Tris pH 7.5). Cellular debris was removed by centrifugation for 2 min at 4000 g, and activity was determined using a protein kinase A assay system (Gibco-BRL).
p44/42 MAPK activity. The retinas were rinsed once with ice-cold PBS, lysed with ice-cold lysis buffer [20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerolphosphate, 1 mM Na 3 VO 4 , 1 mg/ml leupeptin and 1 mM phenylmethylsulfonyl¯uoride (PMSF)] and kept on ice for 5 min, then sonicated four times for 5 s on ice. The samples were centrifuged for 10 min at 4°C and the supernatant was transferred to a fresh tube. Approximately 200 mg of total protein in each sample was used to L.B.Chiarini et al.
immunoprecipitate the active MAPK in the cell extract using an immobilized phospho-p44/42 MAP kinase monoclonal antibody (New England Biolabs non-radioactive kit). MAPK activity was evaluated by incubation with Elk-1 substrate, followed by eletrophoresis and western blotting with anti-phospho-Elk-1 (NEB). Phospho-MAPK was detected by western blotting using speci®c antibodies (NEB). Loading control was performed by western blotting of the supernatant with an antibody to actin (Sigma, 1:200) .
